COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Aakash Desai(University of Connecticut), Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Ishwaria M. Subbiah(The University of Texas MD Anderson Cancer Center), Enrique Grande(MD Anderson Cancer Center Madrid), Aparna Hegde(University of Colorado Cancer Center), Sumanta K. Pal(City of Hope), Roman Groisberg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen V. Liu(University of Southern California), Benjamin Solomon(Peter MacCallum Cancer Centre), Marc Matrana(Ochsner Medical Center), Gilberto Morgan(Skåne University Hospital), Toni K. Choueiri(Dana-Farber Cancer Institute), Tomislav Dragovich(The University of Texas MD Anderson Cancer Center), Haeseong Park(Washington University in St. Louis), Sant P. Chawla(Hematology Oncology Associates), Pashtoon Murtaza Kasi(Cornell University), Justin F. Gainor(Massachusetts General Hospital), Balázs Halmos(University Hospitals of Cleveland), Shumei Kato(University of California San Diego), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Alison M. Schram(Memorial Sloan Kettering Cancer Center), Giuseppe Curigliano(European Institute of Oncology), Neeraj Agarwal(Huntsman (United States)), Herbert H. Loong(Memorial Sloan Kettering Cancer Center)
Cited by 140
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Colorectal cancer
|The Lancet|2019|5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k